Denali Therapeutics clinical trials we track

Check company identity source

Phase 2 / 3 2 trials

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)NCT06602193BIIB122 225 mgActive not recruiting2027-03Estimated

Phase 1 / 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent change from baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A). After: Measure: Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) Measure: Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A).

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 63 participants (planned). After: 65 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source